Analyst Group

Analyst Group Comment on Circio's NOK 300m Capital Raise

Källa: MFN
Positiv

Sammanfattning

Circio Holding ASA har säkrat 300 miljoner NOK genom en kombination av tecknade optioner och en understödd privat placering. Detta, tillsammans med tidigare finansieringar under första halvåret 2026, uppgår det totala kapitalet till cirka 620 miljoner NOK. Kapitalet ska användas för att accelerera plattformsutveckling och driva ett ledande genterapiprogram mot klinisk prövning, med en finansiell räckvidd till slut...

Analys

Finansieringen om 300 miljoner NOK stärker bolagets kapitalposition avsevärt och ger en finansiell räckvidd till slutet av 2030. Denna kapitalanskaffning möjliggör acceleration av plattformsutvecklingen och framsteg i ett ledande genterapiprogram mot IND-ansökan och klinisk proof-of-concept. Den cirka 38-procentiga teckningsgraden indikerar investerares vilja att satsa nytt kapital till en omvärderad aktiekurs. Fokus flyttas nu till exekvering mot kommande katalysatorer, särskilt sjukdomsmodellavläsningar inom ögon och hjärta, samtidigt som den ökade bränningen och den inneboende exekveringsrisken vid intern klinisk utveckling beaktas.

Nyckeltal

Totalt kapital rest i H1-26
ca 620 MNOK
Kapital rest i denna transaktion
300 MNOK
Teckningsgrad för optioner
ca 38%
Finansiell räckvidd
till slutet av 2030

Insikter

  • • Finansieringen om 300 MNOK slutför en anmärkningsvärd vändning i bolagets kapitalposition.
  • • Investerares vilja att satsa nytt kapital vid en omvärderad aktiekurs framgår av teckningsgraden.
  • • Fokus skiftar till exekvering av kommande katalysatorer som nyckel till värdeskapande.
  • • Ökad bränning och risk vid övergång till in-house klinisk utveckling.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 9th of June 2026, that the Company has secured NOK 300m in gross proceeds from the warrant exercise program and a related underwritten private placement. Of the 67,680,945 warrants issued in connection with the February rights issue, 25,781,827 were exercised at NOK 8.2508 per share, a subscription rate of approx. 38%, raising approx. NOK 213m from more than 400 subscribers. The remaining approx. NOK 87m was secured through the underwriting commitment announced on 26 May 2026. Together with the two financings completed earlier in 2026, total capital raised in H1-26 amounts to approx. NOK 620m (USD 65m). The proceeds will be used to accelerate and broaden circVec platform development and to advance a lead gene therapy program towards IND-filing and clinical proof of concept, with an estimated financial runway to the end of 2030.

Circio Holding ASA (”Circio” or ”the Company”) announced, on the 9th of June 2026, that the Company has secured NOK 300m in gross proceeds from the warrant exercise program and a related underwritten private placement. Of the 67,680,945 warrants issued in connection with the February rights issue, 25,781,827 were exercised at NOK 8.2508 per share, a subscription rate of approx. 38%, raising approx. NOK 213m from more than 400 subscribers. The remaining approx. NOK 87m was secured through the underwriting commitment announced on 26 May 2026. Together with the two financings completed earlier in 2026, total capital raised in H1-26 amounts to approx. NOK 620m (USD 65m). The proceeds will be used to accelerate and broaden circVec platform development and to advance a lead gene therapy program towards IND-filing and clinical proof of concept, with an estimated financial runway to the end of 2030.

In summary, Analyst Group considers the NOK 300m financing to complete a remarkable turnaround in the Company’s capital position, bringing total H1-26 proceeds to approx. NOK 620m (USD 65m) and equipping the Company to invest more heavily across the coming years. The approx. 38% subscription rate signals investor willingness to commit fresh capital at a re-rated share price, while the intent to advance a lead program towards IND-filing marks a meaningful evolution beyond preclinical platform licensing. With funding no longer the constraint, Analyst Group regards execution against the 2026 catalyst pipeline, particularly the disease-model readouts in eye and heart, as the key determinant of value creation, balanced against the elevated burn and execution risk inherent in moving towards in-house clinical development.

Read Analyst Group’s comment here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.